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Hepatitis B surface antigen in urine of hemodialysis patients. As
part of an extensive epidemiological survey of chronic hemodialy-
sis patients in Michigan, hepatitis B surface antigen (HB,Ag) was
identified in the sera of 79 of 701 (11%) patients. Of these patients,
59 were carriers of HBAg for three or more months. Urine
samples were collected from 36 of 39 HBAg carriers having
urinary output. Of these samples, 19 (52%) were positive for
HB,Ag by radioimmunoassay; this was confirmed by specific
antibody neutralization. The HBAg was not identified in the urine
of seven hemodialysis patients who were lacking serum HB,Ag or
in urine samples from three HB,Ag sero-carriers who had normal
renal function. Patients undergoing maintenance hemodialysis ap-
pear to constitute a large reservoir of HBAg chronic carriers. This
study indicates that a minimum of 50% ofpersistent HB,Ag car-
riers who are producing urine have detectable HBAg in single,
randomly timed, unconcentrated urine specimen. These data sug-
gest that urine may represent a potential vehicle for transmission
in nonparenterally acquired hepatitis B.
Antigéne de surface de I'hépatite B dans l'urine de malades en
hémodialyse. Dans le cadre d'une large enquête épidémiologique a
propos des malades en hémodialyse chronique dans le Michigan,
l'antigene de surface de l'hépatite B (HBAg) a été identiflé dans le
serum de 79 parmi 701 malades (11%). Parmi ces malades, 59
étaient des porteurs de HB,Ag depuis 3 mois ou plus. L'urine de 36
des 39 porteurs de HBAg, qui avaient une diurése, a éte recueillie.
Parmi ces 36 urines, 19 (52%) sont positives pour HB5Ag par
radio-immunologie, cc qui est confirmé par Ia neutralisation au
moyen d'anticorps spécifique. Le HB,Ag n'a pas été identiflé dans
l'urine de 7 malades en hémodialyse qui n'avaient pas Ic HB,Ag
sérique et dans l'urine de 3 porteurs de HB,Ag dont les fonctions
rdnales étaient normales. Les malades soumis a l'hémodialyse
iterative paraissent constituer un grand reservoir de porteurs chro-
niques de HB,Ag. Cette étude indique qu'au minimum 5Wo des
porteurs chroniques de HB,Ag qui ont une diurése, ont un HB,Ag
detectable dans un echantilion unique d'urine, preleve au hasard,
non concentré. Ces resultats suggérent quc l'urinc peut étre un
véhicule de transmission de l'hépatitc B acquise par voic non
parcntéralc.
Hepatitis B is an important cause of morbidity and
mortality among patients with end-stage renal dis-
ease. Of additional importance is the risk of infection
for persons having intimate contact with these
patients and/or their secretions. Previous studies [1—
8] have estimated that the prevalence of hepatitis B
infection varies from 0 to 100% among dialysis
patients and up to 40% among hospital personnel
dealing with these patients. Furthermore, up to 61%
of the family members of dialysis patients with a
history of hepatitis B were found to have hepatitis B
surface antigen (HB5Ag) or hepatitis B surface anti-
body (anti-HB) in their sera [2]. Previous studies
have demonstrated HBAg in saliva [9—li], semen
[9], and breast milk [12], suggesting transmission by
these secretions. Other studies have documented
that HB,Ag is present in menstrual blood [13] and in
vaginal secretions [14] of female antigen carriers.
While the exact mode(s) of transmission of hepatitis
B in hemodialysis units remains unclear, previous
epidemiologic studies [2, 3, 15] have neglected the
possible role of urine as a vehicle for the spread of
hepatitis B. Studies [11, 16—22] that have examined
urine as a transmission vehicle involved subjects
with virtually intact glomeruli and no proteinuria.
Presence of hepatitis antigen in the urine of each of
seven renal transplant recipients has been reported
[23]. Because of the impaired glomerular permeabili-
ty of patients who have end-stage renal disease, and
since many of these patients produce significant
amounts of urine, this study was undertaken to
examine a large population of these patients to deter-
mine the incidence of HB,Ag-positive urine.
Methods
This study is part of an epidemiologic survey of
dialysis patients which involves 27 of 29 hemodialy-
sis units in Michigan. In this survey, 701 patients of a
possible 800 on center chronic hemodialysis were
studied. There were 59 patients identified as persis-
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tent carriers of HBAg for a period ranging between
three months and three years. An additional 20
patients were discovered to be antigenemic during
the initial survey sampling and are not included in
this study.
Urine specimens were obtained from 36 of the 59
persistent HB5Ag carriers. Of the remaining 23 per-
sistent carriers, 13 were anephric, 7 had no urinary
output, and in 3 cases cooperation in obtaining speci-
mens was lacking. In addition, 7 urine specimens
were obtained from hemodialysis patients who were
HBAg-negative, and 3 urine specimens were
obtained from healthy carriers of serum HB5Ag. All
urine samples were coded and stored at —20°C. Sam-
ple volumes ranged from 5 to 200 ml, and they were
not concentrated prior to testing.
All urine specimens were tested for HBAg by
radioimmunoassay (Ausria 11-125, Abbott Laborato-
ries). Two-tenths of a milliliter of unconcentrated
urine was incubated in wells for 16 hr at 20 to 23°C
(room temperature) with anti-HB-coated beads.
After incubation, the beads were washed three times
with 5 ml of glass distified water, and '251-labeled
anti-HB, was added to each well. The samples were
then incubated for 60 mm in a 45°C water bath, and
the beads were rinsed, as described above. The
residual radioactivity on each bead was counted
immediately in a gamma-counter for 60 sec. The net
negative control mean value was calculated from
data obtained from seven beads that reacted with a
single-source urine sample from an HB5Ag negative
individual. The urine samples with 2.1 times the net
negative control value were considered as presump-
tive positives for HB5Ag.
Urine specimens positive for HB5Ag by the above
method were confirmed using the specific antibody
Confirmatory Neutralization Test (Ausria 11-125, Ab-
bott Laboratories) rather than other licensed but less
sensitive HBAg test systems. Initial incubation and
washing of antibody-coated beads with unconcen-
trated urine was performed as above. Human anti-
HB. was added then to the wells for neutralization of
bound patient HBAg during an incubation at 45°C
for one hour. '25I-anti-HB was subsequently added
to the wells without washing. After incubation at
45°C for three hours, the contents of the wells were
aspirated, washed, and transferred to tubes for
gamma scintillation spectrometry. The net negative
control mean was calculated from data obtained from
seven beads incubated with urine from an HB5Ag
non-reactive individual. A presumptive positive sam-
ple was considered a confirmed positive for HB5Ag if
50% or more of the radioactivity was inhibited by
specific antibody.
All urine samples were tested for the presence of
protein and occult blood by Bili-Labstix (Ames
Company).
Results
Of the 36 urine samples collected from persistent
serum HBAg carriers, 20 (55%) were positive for
HB5Ag by radioimmunoassay. Nineteen of these
positive urines were confirmed by specific neutrali-
zation, and suppression of radioactivity by neutraliz-
ing antibody was usually much greater than 50%.
Only one initially reactive urine specimen could not
be confirmed.
Figure 1 shows the distribution of corrected counts
per minute from urine samples of both HBAg sero-
positive and sero-negative end-stage renal disease
patients. In addition, the counts per minute from
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Fig. 1. Corrected counts per minute of'25I-anti-HB bound in urine
samples from: A, persistent HB,Ag sero-positive, end-stage renal
disease patients with HB,Ag in urine (mean of 19 patients); B,
persistent HBg sero-positive end-stage renal disease patients
without HB)Ag in urine (mean of 17 patients); C, HBAg sero-
negative end-stage renal disease patients (mean of7 patients); ana
D, healthy sero-carriers of HB,Ag without renal disease (mean of
3 patients). The bracketed lines indicate 1 SEM.
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Table 1. Urine HBAg and occult blood in persistent
sero-positive HBAg in patients with end-stage renal
disease
Urine occult
blood
Urine HBAg
Positive Negative
Positive 5 2 3
Negative 31 17 14
Total 36 19 17
urine samples of three sero-positive persons without
renal disease are included. HBAg was not found in
any of the seven urine specimens from dialysis
patients without detectable serum HBAg, nor in
three urine specimens from healthy individuals who
are carriers of HBAg in their sera.
As shown in Table 1, occult blood was found in
five urine specimens of the 36 samples obtained from
dialysis patient carriers of HBAg, but only two of
these were found to contain HBAg. None of the
urine samples from seven sero-negative end-stage
renal disease patients or three healthy carriers
showed the presence of occult blood. All 36 speci-
mens collected from patients having end-stage renal
disease exhibited proteinuria, but none of the urine
samples from three healthy carriers exhibited
proteinuria.
Among sero-positive hemodialysis patients, serum
transaminase activities, bilirubin levels, age, sex,
duration of hemodialysis, duration of HB8Ag carrier
state, volume of urinary output and the original
nature of end-stage renal disease were not signifi-
cantly different by analysis of variance (P > 0.05) in
patients with or without HBAg in their urine.
Discussion
Using a solid-phase radioimmunoassay to detect
HBAg in unconcentrated urine samples, we have
demonstrated HBAg in 52% of the urine specimens
from hemodialysis patients who are persistent car-
riers of HBAg in their sera. This finding is not
related to the presence of gross or occult blood in the
urine. Verification of presumptive HBAg positive
urine samples was accomplished using a specific
human anti-HB, neutralization assay.
There are conflicting reports regarding the pres-
ence of HBAg in urine. Ogra [18] has shown that
viruria is detectable in a small number of hepatitis
patients for a short time in comparison to fecal shed-
ding of virus. In their study of seven renal transplant
recipients who had become chronic serum carriers of
hepatitis antigen, Blainey et al [23], using a comple-
ment fixation test, detected low levels of antigen in
the unconcentrated urine of each patient. The pres-
ence of hepatitis antigen in the urine samples from
these patients may be linked to residual output from
their original kidney(s). Apostolov et al [19] have
reported Australia antigen in the urine from 8 of 13
sero-positive patients with acute viral hepatitis, and
in 4 of 13 sero-positive patients with chronic liver
disease; however, they also reported Australia anti-
gen in the urine in 4 of 13 sero-negative patients with
chronic liver disease, and in 2 of 7 healthy volunteers
who were not carriers of Australia antigen in their
serum. In addition, all their HB5Ag positive urines
were detected by the counterimmunoelectrophoresis
assay after 70- to 80-fold concentration of the urine
samples. Also, the antibody used in their study was
obtained from one of the HB8Ag sero-negative
patients who had biliary cirrhosis and who was not
fully characterized.
Heathcote, Tsianides, and Sherlock [17] have
reported that 10% of urine samples collected from 52
patients with acute viral hepatitis were positive for
hepatitis B antigen by the complement fixation tech-
nique. Of the total urines, 62% were positive on at
least one occasion during six months of continued
follow-up study. These authors, however, found that
48% of the household contacts of these patients had
detectable antigen in their urine without being car-
riers of hepatitis B antigen in their serum.
In contrast to the results of Blainey et al [23],
Apostolov et al [19], and Heathcote et al [17], other
reports [11, 21] have shown that only 3 of 130 urine
samples from sero-positive carriers (each of the 3
having occult blood in the urine at the time of testing)
and 1 of 13 urine specimens from HBAg sero-posi-
tive blood donors were positive for HBAg by
radioimmunoassay. Furthermore, no HB5Ag was
detected in the urine of patients with acute or chronic
hepatitis [21] or of blood donor volunteers with ser-
um HB8Ag [22]. Finally, Irwin et al [16], using a
radioimmunoassay, did not detect HBAg in uncon-
centrated urine samples of 43 HBAg sero-carriers. A
100-fold concentration of urine samples from these
patients, however, resulted in seven patients (16%)
showing detectable HBAg.
Our findings indicate that the prevalence of HBAg
in urine of end-stage renal disease patients with
HB5Ag positive serum is substantial. Physiological
mechanisms that might account for this finding, how-
ever, remain unclear. We speculate that altered gb-
merular premeability could account for the substan-
tial number of patients with detectable urine HBAg.
This hypothesis is supported by the finding of quali-
tative proteinuria in all end-stage renal disease
patients in our study and those of Irwin [16] demon-
strating urine HBAg concentrations 100-fold greatet
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than serum in patients with abnormal renal function
and proteinuria. In addition, none of our three
healthy carriers (without proteinuria) have HBAg-
positive urine, and only a small percentage of
patients from previous studies in whom renal func-
tion was presumably not compromised have HBAg-
positive urine.
No significant difference (P > 0.05) in urine output
of the group having HBAg in their urine, vs. those
without, rules out the possibility that HBAg-nega-
tive urine patients had a large volume of dilute urine
resulting in levels of HBAg below the limits of de-
tection by the radioimmunoassay. In fact, several
patients with urine which was positive for HBAg
had a urinary output in excess of 1,000 ml per day. It
would be of interest, however, to monitor those
patients who are negative for HBAg in their urine,
following concentration of the urine specimens and
repeated urine sampling to maximize detection of
viruria.
Hepatitis B infection among hemodialysis patients
is an endemic problem of relatively high frequency.
At the time of this survey, 90% of the 27 hemodialy-
sis units studied reported hepatitis B infections.
Approximately 25,000 patients are being dialyzed
throughout the United States. From the carrier data
in our study, at least 2,750 patients might be expect-
ed to be HBAg carriers at any given time, 1,900
would have significant urine output, and 1,000
patients would have detectable HBAg in the urine.
HBAg in the urine may not correlate with its
infectivity. Further evidence is needed to confirm the
infectivity of urine and to define the characteristics of
infectious urine, particularly to determine if all mor-
phological forms of HBAg, including the whole
virions (Dane particles), cross the glomerulus.
Recent studies [24—261 have suggested that the pres-
ence of DNA polymerase and e antigen in serum of
HBAg-positive patients appear to be indicators of
the relative infectivity of this serum. This is particu-
larly true in non-percutaneous transmitted hepatitis
after small-volume exposure. To our knowledge,
there is no available evidence regarding the presence
of e antigen or DNA polymerase in urine that is
positive for HBAg. There is, however, some evi-
dence suggesting that these two apparent indices of
infectivity are not found in the absence of HBAg in
the serum [261. Thus, it is probable that all urines
positive for HB5Ag are not equally infectious and
that some are not infectious at all. The ability of e
antigen and DNA polymerase to define the relative
infectivity of HB5Ag-positive blood may also apply
to HBAg-positive urine. Until it is certain that all
body fluids, including urine, negative for e antigen
and polymerase are non-infectious, and also until
infectivity tests are available to all dialysis centers,
urine from antigenemic hemodialysis patients should
be considered a potential vehicle for the transmission
of hepatitis B virus.
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